A SARS-CoV-2 protein interaction map reveals targets for drug repurposing | New Voices in Infection Biology
- Date: Jun 24, 2020
- Time: 04:00 PM (Local Time Germany)
- Speaker: Dave Gordon
- University of California, Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
- Location: MPIIB
- Room: Zoom Video Conference
- Host: Marcus Taylor
- Contact: vseminars@mpiib-berlin.mpg.de
If you are interested in joining the seminar, please contact: vseminars@mpiib-berlin.mpg.de
Once registered, you will receive a zoom conference link 30 mins before the talk starts - please sign in using your full name.
Talk abstract:
The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has caused worldwide social and economic disruption. Efforts to treat SARS-CoV-2 have been hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds, and screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents could lead to a therapeutic regimen to treat COVID-19.